											4	D7
۲۸ Please typ	e a plus sig	gn (+) in	side this	box →[1	-]	1		S. Pater	Approve	d for use through 10/3 k Office: U.S. DEPAR ¹ unless it contains a va	PTO/SB/08A (08-00) 1/2002. OMB 0651-0031 IMENT OF COMMERCE slid OMB control number.	151
¶ Under the	Paperwor	rk Reduc	ction Act	of 1995, no	perso	ns are requi	red to r	espand to a collection	Со	mpl te if Kn wn	alid OMB control number.	ECENE
· (Substitute	e for form	n 1449A	/PTO		12		Application	Number	09/687,86	4 I	
	INIEC)RM	ATIC	ON DIS	CL	OŠE	FRAD	Filing Date		10/13/200	<u> </u>	m
	STA	TEM	IENT	BY A	PP	LICAN	Ì	Filstituinet		Jeffrey A	Leaberter	3 7
				sheets as				Group Art Ur Examiner Na			30	-B 77
<u> </u>	—	(use a		of		3		Attorney Doo			69	クラ
	Sheet											つ `
						·	J.S. P	ATENT DOCUM	ENTS	Pag	ges, Columns, Lines,	> -
<u> </u>	. []		U.S. Pa	tent Docum		Name of	Patent	e or Applicant	Date of Publica Cited Docum	nent Pa	Where Relevant ssages or Relevant	1
Exa Initi			Number	Kind C	\ \			ocument	MM-DD-YY 10/5/9	9 03.21-28.1	Figures Appear 06.34-65, ρ.9 2-7	\exists
		US	5962	2406	1	Armita Armita	ge e	t al.	11/9/9	9 63,21-28.	06.34-65, 09.2-	<u>'</u> -
		US	5598: 55540	1924	1/2	Aruffo	et	al	7/30/9	6 108.1-59	P11.48-56	.55-65, 98.
-		115	35698	3679		Vemaze	e e	t al	12/16/	00 03.40-67.6	4.1-8, p4.66-67, ps	.1-18
		US	s608	6875		Blumbe	rg	et al.	8/19/9	7 11.13-20	1	
		us	s 565	8762_		Zanett Bluest	one	et al.	9/15/0	00 Fig. 1B, F	ig 1C, p.7 lines 38-67	P. B. Innes
		 U	s611	3901		DIUES.			 			\Box
									-			
 		-+							 			
-					Ι				 			
					┼							
ļ.					+							
<u></u>												
Į					+-	 			 			
1					+-	 						
Ļ												\neg
							FORE	IGN PATENT D	11	Date of Publication of	Pages, Columns, Lines, Where Relevant	1
	Examiner	Cite		Foreign F	atent	Document Kind	Code ⁵	Name of Pat Applicant of Cite	entee or	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
	Initials	No.1	Office ³	Num	nber⁴	(if ki	nown)			WWW 25 T. T.		
1												
		 	 -									
	 -		+									
	<u> </u>											
12004-788BHY	- mana	0004 0	168780	4	>						<u> </u>	++
)/2001 JADDU T		-		0.00.00						 		
C+126		+					-	 		<u> </u>		
		1	1	l			↓	 			•	
										Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → +	FEB 2
Under the Paperwork Reduction Act of 1995, no persons	are aquired to
	7840

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

to respond the collection of information unless it contains a valid OMB control number.

ADELAND.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3 Attorney Docket Number

C mplete if Known

Application Number 09/687,864

Filling Date 10/13/2000

First Named Inventor Jeffrey A. Ledbetter

Group Art Unit

Examiner Name

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		HOWELL, A.L., ET AL., "Targeting HIV-1 to FcgammaR on human	
		phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells." J. of Leuk. Biol. 55: 385-391 (1994).	
		ZAGHOUANI, H., ET AL., "Induction of antibodies to the human immunodeficiency virus type I by immunization of baboons with	
		immunoglobulin molecules carrying the principal neutralizing	
		determinant of the envelope protein." PNAS 92: 631-635 (1995)	٠
	1	SYRENGELAS, A.D., ET AL., "DNA Immunization induces protective	П
		immunity against B-cell lymphoma." Nature Med. 2: 1038-1041 (1996).	
		LIU, C., ET AL., "Fcgamma RIII on Human B Cells Can Mediate Enhanced Antigen Presentation." Cell. Immunol. 167: 188-194. (1996).	
		LIU, C., ET AL., "FcgammaRI-Targeted Fusion Proteins Result in Efficient Presentation by Human Monocytes of Antigenic and Antagonist T Cell Epitopes." J. Clin. Invest. 98: 2001-2007.	1 1
		(1996).	
		GUYRE, P.M., ET AL., "Increased Potency of Fc-receptor-targete antigens." Cancer Immunol. Immunother. 45: 146-148 (1997).	đ

		· · · · · · · · · · · · · · · · · · ·
Examiner	Date	
Signature	Consid r d	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box -> + EB 2	PTO/SB/08B (08-00) Approved for use through 10/31/2002. OMB 0651-0031 Approved for use through 10/31/2002. OMB 0651-0031 Approved for use through 10/31/2002. OMB 0651-0031 Approved for use through 10/31/2002. OMB control number. Spend to a 60/ection of information unless it contains a valid OMB control number. Compl te if Known
Under the Paperwork Reduction Act of 1993, No persons	
Substitute for form 1449B/PTO	Application Number 09/007,004
INFORMATION DISCLOSURE	Filing Date 10/13/2000
STATEMENT BY APPLICANT	First Named Inventor Jeffrey A. Ledhetter Group Art Unit
STATEMENT BY AFTERNAL	Group Art Unit
(use as many sheets as necessary)	Group Art Unit Examiner Name Attorney Docket Number
1 3	Attorney Docket Number
Sheet ~ Oi ·	9)

Sheet		01
		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS
		OTHER PRIOR ART – NON PATENT LIBERT (IN CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the Include name o
	0.11	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), and item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).
Examiner nitials*	Cite No.1	item (book, magazine, journal, senai, symposium, catalog, etc.) publisher, city and/or country where published.
	-	BOYLE, J.S., ET AL., "Enhanced responses to a DNA vaccine BOYLE and the second responses to a DNA vaccine immune
	1	
	1	encoding a fusion antigen only induction." Nature 392: 408-411 (1998).
	+	Induction. Results y
	'	
	1	GUYRE, P.M., ET AL., "Macrophage-targeted killing and vaccines."
	+-	GUYRE, P.M., ET AL., "Macrophage-targeted Allers
	1	Res. Tmmunol. 149: 0)
	1	test on of MultivalentAntigens
	\neg	SERRE, K., ET AL., "Efficient Presentation of Mainting Cells Targeted to Various Cell Surface Molecules of Dendritic Cells Targeted to Various Cell Surface Molecules of Dendritic Cells Targeted to Various Cells Surface Molecules of Dendritic Cells Targeted to Various Cells Surface Molecules of Dendritic Cells Targeted to Various Cells Surface Molecules of Dendritic Cells
		Targeted to Various Cell Surface Molecules of Lampunel 1614
		and Surface Ig of Antigen specials
	7	6059-6067. (1998).
	-	
		RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1
		RODRIGUEZ, D., ET AL., "A human immunoderication factor fusion Env-granulocyte macrophage colony-stimulating factor fusion env-granulocyte macrophage response to Env in a
1	1	Env-granulocyte macrophage colony, marronse to Env in a
<u> </u>		Env-granulocyte macrophage colony-stimulations to Env in a protein enhances the cellular immune response to Env in a protein enhance the cellular immune response to Env in a protein enhance the cellular immune response to Env in a protein enhance the cellular immune response to Env in a protein enhance the cellular immune response to Env in a protein enhance the cellular immune response to Env in a protein enhance the cellular immune response to Env in a protein enhance the cellular immune response to Env in a protein enhance the cellular immune response to Env in a protein enhance the cellular immune response to the cellular immune r
		protein enhances the cellular immune response to accinia virus-based vaccine." J. of Gen Virol. 80: 217-223.
İ	- 1	
		a homokines to a sell
		BIRAGYN, A., ET AL., "Genetic Tusion of Chemometer antitumor
1	1	BIRAGYN, A., ET AL., "Genetic fusion of chemokines to the state of the
		tumor antigen induces protective, 153258. (1999). immunity." Nature Biotech. 17: 253-258. (1999).
l	1	
L		
1	1	
1		
1	- 1	
1	-	
-	-+	
1	1	
1	- }	
	- 1	
1	1	
L		

		Date	
Examiner		Consid red	
Signatur	NDED &	O Draw line through	h citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.